4 Contributing Authors Cyrille Cornelio, PharmD, BCCP, is a board-certified cardiology pharmacist passionate about optimizing patient safety and outcomes, with special interests in heart failure, inflammation in cardiovascular disease, transitions of care and informatics. After receiving her doctor of pharmacy from Northeastern University, she completed a general pharmacy residency at Montefiore Medical Center in New York and a cardiology pharmacy residency at the University of Oklahoma. Dr. Cornelio is currently an assistant professor at the University of South Florida (USF) Health Taneja College of Pharmacy and an ambulatory care clinician collaborating with providers to optimize patient care within USF Health Cardiology. She is also an active member on the American Heart Association’s Clinical Pharmacology Committee and Committee on Scientific Sessions Program. Disclosures: Nothing to disclose Michael Garshick, MD, is an assistant professor of medicine and dermatology at NYU Langone Health. He graduated from Tufts University School of Medicine with Alpha Omega Alpha honors. He completed an internal medicine residency at Columbia University Medical Center and a cardiology fellowship, T32 research fellowship and a master’s program in clinical investigation at NYU Langone Health. Dr. Garshick’s s clinical and research interests include exploring mechanisms and therapeutics to treat cardiovascular disease in patients with immune-mediated inflammatory diseases. He conducts clinical trials and directs the cardio-rheumatology program at NYU Langone Health dedicated to reducing cardiovascular risk in patients with heightened systemic inflammation. Dr. Garshick has held grants from the New York Medical Society, National Psoriasis Foundation, Dermatology Foundation, American Heart Association and the NIH/NHLBI. Disclosures Employment: NYU Langone Medical Center Professional Services and Activities: Agepha, Horizon Pharma plc, Kiniksa Pharmaceuticals, Bristol Myers Squibb Tevfik F. Ismail, MBBS, PhD, is a consultant cardiologist at Guy’s and St. Thomas’ Hospital and a reader/associate professor at King’s College London, London, U.K. He is clinical lead for inflammatory myocardial and pericardial diseases and deputy clinical lead for the adult noncongenital cardiovascular magnetic resonance clinical service. He is a fellow of the Society for Cardiovascular Magnetic Resonance, the American College of Cardiology, European Society of Cardiology, the Higher Education Academy, the Royal College of Physicians and the American Heart Association. He is the cardiology editor for Clinical Medicine, the Journal of the Royal College of Physicians. His clinical and research interests include inflammatory myocardial and pericardial disease, inherited cardiac conditions, heart failure, magnetic resonance elastography, myocardial mechanics and advanced imaging methods for the assessment of non-ischemic heart muscle disease. Disclosures: Nothing to disclose Sachin Kumar, MD, is a cardiovascular fellow at Mount Sinai Morningside in New York City, with a keen interest in pericardial diseases, especially recurrent pericarditis. Driven by a passion for both patient care and education, Dr. Kumar is actively involved in research. He has contributed to the field through his publications focusing on advances in imaging and targeted therapies, which have led to a paradigm shift in managing recurrent pericarditis. He aspires to further his training with a fellowship in interventional cardiology and to advance the understanding and treatment of pericardial diseases through continued research and collaboration. Disclosures: Nothing to disclose The American Heart Association is committed to ensuring balance, independence, objectivity and scientific rigor in its certified educational activities. All faculty, planners and contributors in a position to control the content for an AHA-sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational. Relationship disclosures within the past 24 months:
RkJQdWJsaXNoZXIy MjI2NjI=